Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1841-1860 of 2,120 trials

Pancreatic Head Cancer: Neoadjuvant Chemotherapy Study

We are exploring whether giving chemotherapy before surgery helps improve survival for patients with resectable pancreatic head cancer compared to surgery alone. This study aims to find better treatment strategies to reduce early mortality.

Resectable Pancreatic Head Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesOncology

Advanced NSCLC: Roginolisib with Dostarlimab

We are studying a new treatment combination for patients with advanced non-squamous lung cancer who have not responded to standard therapies. The trial will evaluate safety and early signs of effectiveness.

Advanced Non-Squamous Non-Small Cell Lung CancerSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncologyPulmonology

End-of-Life Care: Midazolam and Morphine Study

We are investigating how midazolam and morphine can help relieve pain and discomfort in elderly patients during their final days. This study aims to understand the best dosing strategies and any potential side effects.

Symptom Treatment in End-of-Life Care for Geriatric Patients1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGastroenterologyInternal Medicine

Cardiac Surgery: Angiotensin II vs. Noradrenaline

We are studying whether angiotensin II can better prevent kidney injury compared to noradrenaline in patients undergoing cardiac surgery. This research may help improve kidney health outcomes after surgery.

Acute Kidney Injury>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboInvestigational MedicinesPartially RemoteCardiologyInternal MedicineNephrology

Lung Cancer Treatment: Rilvegostomig vs. Pembrolizumab

We are studying a new drug, rilvegostomig, to see if it works better than pembrolizumab for patients with PD-L1-high metastatic non-small cell lung cancer. This trial aims to understand which treatment may improve survival and quality of life.

Lung CancerConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Metastatic Renal Cell Carcinoma: Immunotherapy and Tumor Treatment Study

We are studying how surgery and radiation affect survival and tumor growth in patients with metastatic renal cell carcinoma receiving immunotherapy. This trial aims to improve treatment strategies and quality of life for these patients.

Advanced Kidney Cancer1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncology

Hemophilia A: Efanesoctocog Alfa Treatment Study

We are studying the long-term effects of efanesoctocog alfa on joint health in people with hemophilia A. The trial aims to see how well it prevents joint bleeds and improves quality of life.

Haemophilia A1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementHematologyOrthopedics and Traumatology

Advanced Non-Small Cell Lung Cancer: M9140 Treatment Study

We are studying a new drug called M9140 for people with advanced non-small cell lung cancer. The goal is to see how well it works and how safe it is compared to existing treatments.

Non-Small Cell Lung Cancer6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Advanced Pancreatic Cancer: M9140 Treatment Study

We are studying a new drug called M9140 for people with advanced pancreatic cancer to see how well it works and how safe it is. This trial aims to evaluate its effectiveness and side effects compared to standard treatments.

Metastatic Pancreatic Cancer6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Chronic Urticaria: Briquilimab Study

We are studying the long-term safety and effectiveness of briquilimab in people with chronic urticaria. This trial includes participants from earlier studies to see how well the treatment works over time.

Chronic UrticariaEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesAllergologyDermatology

High-Risk Melanoma: Neoadjuvant Pembrolizumab Study

We are studying the effects of pembrolizumab in patients with high-risk melanoma who have no signs of spread. The goal is to see if this treatment can improve outcomes before surgery.

Melanoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesDermatologyOncology

DAVINCY Trial: (fos)Aprepitant for Nausea in Children

We are studying whether a longer duration of (fos)aprepitant can better prevent nausea and vomiting in children receiving chemotherapy. This trial compares the standard treatment with an extended regimen to find the most effective approach.

Delayed Chemotherapy Induced Nausea and VomitingConfirmation phase (III)Investigational MedicinesPartially RemoteInternal MedicineOncologyPediatrics

Soft Tissue Sarcoma: Pembrolizumab with Radiotherapy

We are studying whether adding pembrolizumab to radiotherapy before and after surgery helps patients with high-risk localized soft tissue sarcoma live longer without disease recurrence. This trial compares this approach to standard treatment with radiotherapy and surgery alone.

High-Risk Soft Tissue Sarcoma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyOrthopedics and Traumatology

Moderate-to-Severe Asthma: PF-07275315 Study

We are investigating a new medication called PF-07275315 for adults with moderate-to-severe asthma. The study aims to see if it is more effective than a placebo in improving asthma control and quality of life.

Moderate-to-Severe Asthma6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementAllergologyPulmonology

Hydrocortisone Treatment in Pancreatoduodenectomy Surgery

We are studying whether hydrocortisone infusions can help reduce complications after pancreatoduodenectomy surgery. This trial compares the effects of hydrocortisone to a placebo in patients undergoing this procedure.

Pancreatic Resection>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

ANCA-Associated Vasculitis: Rituximab Treatment Study

We are comparing a combination of rituximab and cyclophosphamide to standard treatment for achieving remission in severe ANCA-associated vasculitis. The trial also looks at how different ways of giving rituximab can help maintain remission.

ANCA-Associated Vasculitis6-12 monthsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineRheumatology

Infant Immunity to Whooping Cough: Maternal Vaccination Study

We are studying how vaccines given to pregnant women affect their infants' immunity to whooping cough. Our goal is to find out what factors influence the transfer of protective antibodies from mothers to their babies.

Whooping Cough>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementGynecology and ObstetricsInfectious DiseasesInternal Medicine

Knee Osteoarthritis: SYN321 Injection Study

We are testing a new injection for people with knee osteoarthritis to see if it is safe and effective. The study compares different doses of SYN321 to a placebo to assess its impact on symptoms.

Knee Osteoarthritis≤3 monthsSafety phase (I)Efficacy phase (II)Investigational MedicinesInternal MedicineOrthopedics and Traumatology

Midgut Neuroendocrine Tumors: Lu177-Dotatate Treatment Schedule

We are studying whether giving Lu177-Dotatate every 16 weeks can lower serious side effects for patients with advanced midgut neuroendocrine tumors. This trial compares the new schedule to the standard treatment given every 8 weeks.

Small Intestine Neuroendocrine Tumor>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyOncology

Small Cell Lung Cancer: MK-6070 and Ifinatamab Deruxtecan Study

We are studying the safety and effectiveness of MK-6070 combined with ifinatamab deruxtecan in people with advanced small cell lung cancer. This trial aims to find better treatment options for those whose cancer has returned or is hard to treat.

Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesOncology